Acasti Pharma Inc. (ACST)
ACST Price and Sentiment
ACST Latest news
Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan2021-10-06 08:30
Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage2021-09-27 08:30
Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022 Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards2021-09-22 08:30
LAVAL, Québec, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq's minimum bid price requirement.
LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.
The clinical-stage pharmaceutical company completed its merger with Grace Therapeutics last week.
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split2021-08-27 08:40
LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management's current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D'Alvise as President and Chief Executive Officer, under the oversight of Acasti's newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and com
Making a penny stocks watchlist in August? Check these 3 small-caps out The post Are These Penny Stocks on Your Watchlist Right Now?
August 4 th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company's website
Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics2021-07-29 08:30
LAVAL, Québec, July 29, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces a reminder that it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases, as well as topics related to the annual and special meeting of shareholders. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to ACST@crescendo-ir.com.
Which penny stocks are investors watching with August only a week away? The post Best Penny Stocks to Buy in August?